Form PRE 14A - Other preliminary proxy statements:
SEC Accession No. 0001193125-24-097724
Filing Date
2024-04-16
Accepted
2024-04-16 16:05:47
Documents
20
Period of Report
2024-06-07

Document Format Files

Seq Description Document Type Size
1 PRE 14A d747644dpre14a.htm   iXBRL PRE 14A 880830
6 GRAPHIC g747644g01g02.jpg GRAPHIC 56899
7 GRAPHIC g747644g56a01.jpg GRAPHIC 80888
8 GRAPHIC g747644g57a01.jpg GRAPHIC 83167
9 GRAPHIC g747644g83a01.jpg GRAPHIC 214224
10 GRAPHIC g747644g84a01.jpg GRAPHIC 151232
  Complete submission text file 0001193125-24-097724.txt   3254663

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA fate-20231231.xsd EX-101.SCH 5723
3 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE fate-20231231_def.xml EX-101.DEF 5837
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE fate-20231231_lab.xml EX-101.LAB 8782
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE fate-20231231_pre.xml EX-101.PRE 5314
23 EXTRACTED XBRL INSTANCE DOCUMENT d747644dpre14a_htm.xml XML 265610
Mailing Address 12278 SCRIPPS SUMMIT DRIVE SAN DIEGO CA 92131
Business Address 12278 SCRIPPS SUMMIT DRIVE SAN DIEGO CA 92131 858.875.1803
FATE THERAPEUTICS INC (Filer) CIK: 0001434316 (see all company filings)

EIN.: 651311552 | Fiscal Year End: 1231
Type: PRE 14A | Act: 34 | File No.: 001-36076 | Film No.: 24847834
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)